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a b s t r a c t
Castleman's disease (CD) is a rare lymphoproliferative disorder characterized by atypical
lymph node follicular hyperplasia. Subsequential occurrence of CD and cancers has been
rarely reported and interpretations of the relationship are contentious. An asymptomatic
70-year-old man was found to have a left-sided hilar mass during routine follow-up after
a radical right nephrectomy for clear cell carcinoma, raising suspicions of lung metasta-
sis. Because there was no sign of recurrence in the original operative region, he under-
went wedge resection of the left lung and lymph nodes dissection. Histology showed
typical features of HVCD. Herein, we emphasize careful histopathology and complete
resection of CD. We speculate that subsequential occurrence of CD and cancers may not
be coincidental and warrants further exploration.
© 2014 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Castleman's disease is a rare atypical lymphoproliferative
disorder, consisting of two main entities – UCD (Unicentric
Castleman's Disease) and MCD (Multicentric Castleman's
Disease) with different characteristics [1, 2]. Coexistence or
subsequential occurrence of CD and other malignancies has
been rarely reported, and explanations other than coinci-
dence are contentious [3–8].* Corresponding author at: Tianjin Medical University Cancer Institu
China. Tel.: +86 03708772869; fax: +86 22 23558988.
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An asymptomatic 70-year-old man was found to have an
enhancing right renal mass during a routine workup in
a computed tomography inspection (CT) (Fig. 1). A chest X-
ray and all preoperative laboratory findings were normal. He
underwent a radical right laparoscopic nephrectomy for
suspected renal cell carcinoma. Gross pathology examina-
tion demonstrated a ductile, red and pale mass, limited tote and Hospital, Tianjin Hexi District, Huanhuxi Road, Tianjin,
ów, Instytut Hematologii i Transfuzjologii. Published by Elsevier
Fig. 1 – Contrast-enhanced CT image of the abdomen showing an enhancing mass, highly suspicious for malignancy (as the
arrow showed). Hematoxylin-eosin stained photo-micrograph shows typical pathology of clear cell renal cancer
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cell carcinoma was confirmed on histology (Fig. 1). Observa-
tion was suggested as per National Comprehensive Cancer
Center guidelines (Version 2. 2014). Follow-up CT and US
(ultrasound) were normal until a CT (Figures not shown)
demonstrated a distinct left-sided hilar mass two years
postoperatively. A subsequent PET-CT (positron emission
tomography/computed tomography) scan confirmed anFig. 2 – An abnormal soft tissue mass with increased 18F-fluorod
no evidence recurrence in the original operative region (as the aabnormal soft tissue mass with increased 18F-FDG (18F-
fluorodeoxyglucose) uptake in the inferior lobe of left lung
near the diaphragm, raising suspicions of malignancy, but
no sign of recurrence in the original operative region (Fig. 2).
All preoperative laboratory findings including CRP (C reac-
tive protein), ESR (Erythrocyte sedimentation rate) were
normal. Etiologic testing including HIV (human immunodefi-
ciency virus) antibody and HHV8 (human herpes virus 8)eoxyglucose accumulation suspicious for malignancy, with
rrows showed)
Fig. 3 – (A) Typical histologic features of Castleman's disease with hyaline vascular variant. Hematoxylin–eosin stained photo-
micrograph shows the classic 'onionskin' appearance in immunohistochemistry. (B) Bcl-2 negative. (C) CD3 partially positive.
(D) CD5 partially positive. (E) CD20 prominently positive. (F) CD21 follicular negative. (G) Ki-67 20% positive. (H) cyclinD1
negative (all of the photomicrographs are presented with magnification of 4T and 20T)
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lung metastasis, he underwent a wedge resection of the left
lung and the 7, 9, 11 groups lymph nodes dissection. Histolo-
gical sections of the mass revealed typical features of HVCD:
many lymphoid follicles with hyalinized germinal centers and
broad mantle zones, showing the classic 'onionskin' appear-
ance, with vascular proliferation prominent in the germinal
centers and the interfollicular areas in HE staining (Fig. 3A).
The IHC (immunohistochemistry) showed blow (Fig. 3B–H),
confirmed the HVCD histology. Observation and regular check-
up were suggested. Until now, there is no sign of reoccurrence.
Discussion
Benjamin Castleman first reported the rare lymphoprolifera-
tive disorder that bears his name in 1954 [1]. CD is
a heterogenous disease separated into two entities clinically –
UCD (unicentric Castleman's disease) and MCD (multicentric
Castleman's disease), with distinct treatment algorithms and
prognosis. CD is further divided into three variants histo-
pathologically. The plasma cell and mixed type usually
present as MCD, often associated with constitutional symp-
toms and require systematic therapy [5]. The hyalinized
vascular type accounts for 90% of UCD, is often asymptomatic
at presentation, and has a high cure rate with surgical
excision [9]. Complete resection is required as recurrence
following surgery does occur in a minority of UCD cases [10].
Relation with cancers
While CD is a group of benign lymphoproliferative disorder,
there are complex relationships between CD and malignan-
cies. Although rapidly improving imaging techniques exists,
especially PET-CT, may failed to differentiate CD and can-
cers. [11, 12]. Recent reports show that CD can mimic
neoplasm causing diagnostic dilemmas requiring pathology
to resolve [12, 13]. As in this case, diagnosis may be difficult
to ascertain and should rely on histology.
Concomitant or subsequential occurrences of CD and
malignancies including lymphoma, melanoma, Kaposi's sar-
coma, melanoma, hepatocellular carcinoma and renal can-
cer have been reported [3–8]. It deserves consideration when
a suspicious mass is present. In this case, CD in the
mediastinum mimicked lung metastasis of renal cancer.
Complete resection and careful pathology were needed to
guarantee accurate diagnosis and therapy.
Potential theories
Concomitant or subsequential occurrences of CD with can-
cers may be more than coincidental. A number of causal
mechanisms have been proposed.
IL-6 is involved in a wide range of biologic activities, such
as auto-immune disease, chronic inflammatory proliferative
disease and apoptosis resistance [14]. Stimulating B lymphoid
cell proliferation and plasma cell differentiation, high expres-
sion of IL-6 was discovered both in the lymph nodes andserum of CD patients, and fluctuation of IL-6 is correlated
with symptom variation [15]. In recent case reports, Tissier
and Deshmukh attributed CD synchronous with cancers to
dysimmunity caused by IL-6 elevation [3, 4]. Often reported
coexistent with MCD, Kaposi's sarcoma is commonly attrib-
uted to HHV-8 infection [16]. HHV-8 can encode viral IL-6 (vIL-
6) in latently infected cells, which can initiate MCD by binding
to ubiquitously expressed gp130 receptor submit and subse-
quently JAK-STAT pathway [17]. Research on hepatocellular
malignancy showed that elevation of IL-6 is insufficient.
Experiment in vivo suggests that a certain threshold of IL-6
stimulation is required to initiate hepatocellular hyperplasia
[18], whereas a second hit of CTNNB1 (c.121A >G; p.T41A)
mutation is necessary for the development of concurrence of
hepatocellular carcinoma and CD [6]. Siltuximab (a chimeric
human-murine anti-IL-6 antibody) has produced a favorable
response in a case of cutaneous CD [19].
In addition to IL-6, evidence is accumulating that abnor-
mal expression of VEGF (vascular endothelial growth factor)
may be another factor [4, 8]. As an important hallmark of
cancer, angiogenesis links the malignancy and distant metas-
tasis, and frequently appears in the interfollicular space of
CD. Closely correlated with vessel density, VEGF seems to be
the most relevant cytokine in this respect. As for renal
carcinoma, a VHL gene mutation often occurs, activating the
hypoxia-response pathway and inducing transcription of
several genes, including VEGF, and subsequent tumor pro-
gression [20]. Complete resection of CD may be essential to
avert susceptibility to microangiopathy related to VEGF [21].
A single case report discusses the successful embolization
with polyvinyl alcohol microparticles [22].
There are several reports of concurrence of follicular
dendritic cell sarcoma (FDCS) with HVCD [23]. Follicular
dendritic cells are a kind of stromal cells, dysplasia of which
may provide a new pathogenetic hypothesis of HVCD [24].
Discoveries on the chromosomal level have provided genetic
interpretations and give clues that complication of HVCD
and FDCS may not be coincidental [25].
An intriguing question emerges: does CD contribute to
the development of cancers or vice versa? CD was consid-
ered a paraneoplastic phenomenon of spindle cell carci-
noma [5]. When it coexisted with Hodgkin's disease, it was
regarded as a reaction to malignancy [7]. In a case of
occurrence with melanoma, CD was proposed to be
a consequence of VEGF secretion by solid tumors [8].
Conclusion
This case of HVCD mimicking lung metastasis of renal clear
cell carcinoma required careful histopathology and complete
resection of CD. This coexistence of CD and cancer may not
be a coincidence. Further research is warranted to unmark
the relevant occult mechanism.
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